Legal & General Group Plc Sells 181,650 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Legal & General Group Plc trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 18.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 777,477 shares of the biopharmaceutical company's stock after selling 181,650 shares during the period. Legal & General Group Plc owned approximately 0.71% of Regeneron Pharmaceuticals worth $553,820,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. OFI Invest Asset Management purchased a new stake in Regeneron Pharmaceuticals during the fourth quarter valued at $28,000. Rakuten Securities Inc. increased its holdings in shares of Regeneron Pharmaceuticals by 62.5% in the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after buying an additional 15 shares during the last quarter. Avalon Trust Co purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Crowley Wealth Management Inc. purchased a new stake in shares of Regeneron Pharmaceuticals during the 4th quarter valued at about $36,000. Finally, Private Wealth Management Group LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 260.0% in the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 39 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Stock Up 1.4 %

Regeneron Pharmaceuticals stock traded up $7.79 during midday trading on Friday, hitting $554.18. 1,170,894 shares of the company's stock were exchanged, compared to its average volume of 707,716. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The company has a market cap of $60.59 billion, a PE ratio of 14.48, a P/E/G ratio of 2.34 and a beta of 0.44. The firm has a 50-day moving average of $659.94 and a two-hundred day moving average of $753.23. Regeneron Pharmaceuticals, Inc. has a 12 month low of $525.99 and a 12 month high of $1,211.20.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $11.86 earnings per share. As a group, analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.64%. Regeneron Pharmaceuticals's dividend payout ratio is presently 2.30%.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on REGN. Truist Financial decreased their price objective on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a research report on Wednesday, January 8th. Canaccord Genuity Group assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a "hold" rating and a $165.00 price target on the stock. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating for the company in a research report on Monday, January 27th. Sanford C. Bernstein cut their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating on the stock in a research report on Tuesday, January 7th. Finally, JPMorgan Chase & Co. lowered their target price on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an "overweight" rating for the company in a report on Monday, March 31st. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $966.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.